Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
204 studies found for:    Open Studies | "Hodgkin Disease"
Show Display Options
Rank Status Study
21 Recruiting Brain Integrity in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation
Condition: Hodgkin Lymphoma
Interventions: Other: Neurocognitive Evaluation;   Other: Quantitative Brain Imaging;   Other: Neurologic Evaluation;   Other: Health Questionnaire;   Other: Vascular Testing;   Other: Cardiopulmonary Exercise Testing;   Other: Echocardiography;   Other: Pulmonary Function Testing;   Procedure: Serum Biomarkers;   Other: Ophthalmology Examination;   Other: Sleep Assessment
22 Not yet recruiting Social Inequalities in the Participation and Activity in Children and Adolescents With Hodgkin-lymphoma
Condition: Classical Hodgkin Lymphoma
Intervention:
23 Recruiting Dual Point PET Scan in Early Stage Hodgkin Lymphoma Patients With Bulky Lesions
Condition: Hodgkin's Lymphoma
Intervention:
24 Recruiting Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: Mocetinostat Plus Brentuximab Vedotin
25 Recruiting A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: nivolumab
26 Recruiting Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: B-CAP;   Drug: Brentuximab Vedotin
27 Recruiting Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab vedotin (SGN-35);   Drug: Doxorubicin HCL;   Drug: Vinblastine Sulfate;   Drug: Dacarbazine;   Radiation: Involved-Site Radiation Therapy (ISRT);   Procedure: Interim PET;   Radiation: consolidation volume RT (CVRT)
28 Recruiting Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: DHAP;   Drug: Everolimus
29 Recruiting Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Biological: AFM13;   Biological: Pembrolizumab
30 Recruiting Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Biological: CD19 RNA redirected autologous T-cells (RNA CART19 cells)
31 Recruiting Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
Condition: Hodgkin Lymphoma
Interventions: Biological: pembrolizumab;   Biological: brentuximab vedotin
32 Recruiting Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.
Condition: Hodgkin Lymphoma
Interventions: Drug: Doxorubicin;   Drug: Bleomycin;   Drug: Vinblastine;   Drug: Dacarbazine;   Drug: Brentuximab Vedotin
33 Recruiting Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors
Condition: Hodgkin Lymphoma Survivor
Interventions: Other: Clinical Assessment;   Procedure: Stress cardiac MRI;   Procedure: Stress echocardiogram
34 Recruiting Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Conditions: Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Ibrutinib
35 Recruiting Ipilimumab, Nivolumab, and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Conditions: Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
36 Not yet recruiting Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Condition: Classical Hodgkin Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
37 Recruiting Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
Condition: Classical Hodgkin Lymphoma
Interventions: Drug: cyclophosphamide, vincristine, prednisone, dacarbazine;   Drug: cyclo, vcr, pred, dacarb,etop and doxo
38 Recruiting Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin
Condition: Classical Hodgkin Lymphoma
Interventions: Drug: Bendamustine;   Drug: Prednisone;   Drug: Vinblastine;   Drug: Doxorubicin
39 Recruiting Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
Conditions: Hodgkin Disease;   Lymphoma, Large-Cell, Anaplastic
Intervention: Drug: Brentuximab Vedotin
40 Recruiting Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Conditions: Recurrent Adult Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.